



Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test)

Information for the public Published: 17 June 2020

www.nice.org.uk

NICE has assessed the ARCHITECT and Alinity i Urine neutrophil gelatinase-associated lipocalin (NGAL) assays, BioPorto NGAL test and NephroCheck test to help the NHS decide whether to use these products. The tests could be used to detect acute kidney injury earlier than the tests currently in use.

Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test)

NICE has said that these tests are not recommended for people being considered for critical care admission, and further research is needed. This is because it is not clear if the tests would help, for example by shortening the time people spend in hospital or by making dialysis while in hospital less likely.

ISBN: 978-1-4731-7475-7